Compare ICFI & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ICFI | EYPT |
|---|---|---|
| Founded | 1969 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Laboratory Analytical Instruments |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2006 | 2005 |
| Metric | ICFI | EYPT |
|---|---|---|
| Price | $89.73 | $5.43 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $99.25 | $31.80 |
| AVG Volume (30 Days) | 207.7K | ★ 5.1M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.82% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.61 | N/A |
| Revenue | ★ $1,229,162,000.00 | $7,539,000.00 |
| Revenue This Year | $4.12 | N/A |
| Revenue Next Year | $5.33 | $3,115.57 |
| P/E Ratio | $34.13 | ★ N/A |
| Revenue Growth | ★ 3.72 | N/A |
| 52 Week Low | $58.83 | $3.95 |
| 52 Week High | $101.50 | $19.11 |
| Indicator | ICFI | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 60.23 | 29.52 |
| Support Level | $84.28 | N/A |
| Resistance Level | $89.91 | $15.17 |
| Average True Range (ATR) | 3.34 | 0.91 |
| MACD | -0.31 | -0.86 |
| Stochastic Oscillator | 53.91 | 12.07 |
ICF International Inc provides professional services and technology-based solutions, including management, technology and policy consulting and implementation services, to government and commercial clients in the U.S. and internationally. Its government clients include U.S. federal agencies, state and local governments and international governments, as well as commercial clients inside and outside the U.S. It supports clients in Energy, Environment, Infrastructure and Disaster Recovery; Health and Social Programs; and Security and Other Civilian and Commercial markets. The company delivers services across the life cycle of a policy, program or project through Advisory Services, Program Implementation, Analytics Services, Digital Services and Engagement Services.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.